Vivo Capital Mergers and Acquisitions Summary

Growth Capital Firm Profile

In the last 3 years, Vivo Capital has invested in 3 companies.

Vivo Capital’s most common sectors for investment arelife science (73%) and medical products (28%) . The Firm’s most common investment types include venture (73%) and pipe (12%). In total, Vivo Capital has invested in 7 US states and 4 different countries.

In the last 3 years, Vivo Capital has exited 5 companies. The Firm’s most common exit type is ipo (64%). Vivo Capital’s largest (disclosed) exit occurred in 2022 when it sold Sierra Oncology for $2.9B.

Join Mergr to view Vivo Capital’s full profile and discover more large private equity firms just like it.

M&A Summary

  • M&A Total Activity29
    • M&A Buy Activity18
    • M&A Sell Activity11
  • Total Sectors Invested 2
  • Total Countries Invested 4
  • M&A Buy/Sell Connections 12
  • M&A Advisors 1

Vivo Capital

192 Lytton Avenue,
Palo Alto, California 94301
United States
(650) 688-0818
www.vivocapital.com
info@vivocapital.com

Vivo Capital is a healthcare investment firm focused on opportunities throughout the US and China. Specific areas of interest include biopharmaceuticals, specialty pharmaceuticals, and medical devices. The Firm looks to identify and work with companies at the development and commercial stage products in the US and at the revenue stage in China. Vivo Capital was established in 1997 and is headquartered in Palo Alto, California.


Investment Criteria

Sectors of Interest: Life Science, Medical Products

Target Transaction Types: Buyout (LBO, MBO, MBI), Growth Capital, Venture

Geographic Preferences: East US, Midwest US, South US, West US, Asia/Pacific

Transaction Criteria Min Max
Target Revenue - -
Target EBITDA - -
Investment Size - -
Enterprise Value - -

M&A Summary

Buy vs Sell

Year ≤ '17 '18 '19 '20 '21 '22 T
Buy (0.8/yr) # 14 1 1 - 2 - 18
Sell (1.4/yr) # 4 2 2 - 2 1 11
vol $300M $2.9B $3.2B
  29

Most Recent M&A

Company Date Value Type
Sierra Oncology, Inc. 2022-04-13 2.9B GBP Add-on Acquisition
San Mateo, California · www.www.sierraoncology.com
Impel NeuroPharma, Inc. 2021-04-22 - IPO
Seattle, Washington · www.impelnp.com
Surgical Specialties 2021-02-01 - Add-on Acquisition
Westwood, Massachusetts · www.surgicalspecialties.com
IO Biotech ApS 2021-01-13 - Venture
Copenhagen, Denmark · www.iobiotech.com
Seran Bioscience, Inc. 2021-01-05 - Growth Capital
Bend, Oregon · www.seranbio.com
SentreHEART, Inc. 2019-08-12 300M USD Add-on Acquisition
Redwood City, California · www.sentreheart.com
AirXpanders, Inc. 2019-07-16 - Bankruptcy
San Francisco, California · www.airxpanders.com
Minerva Surgical, Inc. 2019-01-04 - Venture
Redwood City, California · www.minervasurgical.com
Weisheng Pharmaceutical (Shanghai) Co., Ltd. 2018-11-08 - Joint Venture
Shanghai, China · www.visenpharma.com
Tricida, Inc. 2018-06-02 - IPO
South San Francisco, California · www.tricida.com
View All >>

M&A by Sector

Sector Current # Value All-time # Value
Life Science 7 (78%) - 13 (72%) -
Medical Products 2 (22%) - 5 (28%) -
Total 9 - 18 -

Acquisitions By Geo

State/Country Current # Value All-time # Value
United States 7 (78%) - 15 (83%) -
  California 2 (22%) - 6 (33%) -
  Massachusetts - - 3 (17%) -
  Pennsylvania 2 (22%) - 2 (11%) -
  Oregon 1 (11%) - 1 (6%) -
  Ohio 1 (11%) - 1 (6%) -
  Indiana 1 (11%) - 1 (6%) -
  Washington - - 1 (6%) -
China 1 (11%) - 1 (6%) -
Denmark 1 (11%) - 1 (6%) -
Ireland - - 1 (6%) -
Total 9 - 18 -

Acquisitions by Deal Type

Type Current # Value All-time # Value
Venture 6 (67%) - 13 (72%) -
PIPE 1 (11%) - 2 (11%) -
Buyout (LBO, MBO, MBI) - - 1 (6%) -
Growth Capital 1 (11%) - 1 (6%) -
Joint Venture 1 (11%) - 1 (6%) -
Total 9 - 18 -

Exits by Deal Type

Type Total # Value
IPO 7 (64%) -
Trade Sale - Public Company 2 (18%) 3.2B (100%)
Bankruptcy 1 (9%) -
Trade Sale 1 (9%) -
Total 11 $3.2B

Top M&A Advisors

Financial Deals
Monroe Capital LLC
 1

Deal Values

sell # Total
> $1B 1 $2.9B
$100M to $1B 1 $300M
TOTAL $3.2B
Largest Sierra Oncology, Inc.
$2.9B (2022-04-13)

M&A Connections

Deals
Exited to
Strategic(s)
27%
3 (27%)

Investor Summary

Investor Type

Growth Capital Firm

Size

Large

PE Assets

3.0B USD

Established

1996

Specialist/Generalist

Specialist

Leadership

Edgar Engleman

Founding Member & Managing Partner

Frank Kung

Founding Member & Managing Partner

Shan Fu

Co-CEO & Managing Partner

Albert Cha

Managing Partner

Chen Yu

Managing Partner

 Subscribe to unlock this and 185,414
investor and company profiles

Sign-up today to get full access

  • check  Unlimited Searches
  • check  Unlimited Profile Views
  • check  Build and Export Lists of
    • PE Backed Companies
    • Direct Investors & Acquirers
    • Advisors
    • Deals
    • & More
1 Week Free Trial Learn More

What's Mergr?

We built Mergr to save people the arduous and time-consuming process of tracking when companies are bought, sold, and who currently owns them.

Every day, new opportunities emerge around M&A and we help professionals of all types comb through transactions, investors, and corporate acquirers via an easy-to-use web database that is accessible to anyone.

Try us for 1 week free today!

Mergr, the Easiest-to-Use PE and M&A DB

Key Benefits

  • Stay informed on events in your industry
  • M&A research that takes seconds (not all afternoon)
  • Better understand your customers and prospects
  • Discover active buyers (or sellers)
Search
  • 4.4K Private Equity Firms
  • 176K M&A Transactions
  • 181K Companies Involved in M&A
    (Buyer, Seller, or Target)
  • 3.5K M&A Advisors
    (Investment Banks and Law Firms)
  • 66K M&A Contacts
    (PE and M&A Advisors)

Ready to try?

Join FREE for 1 Week

No obligation. Cancel anytime.

Mergr

Product

Company

Legal